Test Price
2,800 AED✅ Home Collection Available
FCRL6 Gene Genetic Test (NGS) for Autism Spectrum Disorder Susceptibility in UAE
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- ✓ Clinical Guidance: Telephonic post-test clinical guidance for result interpretation provided by a Consultant Medical Geneticist.
- ✓ Insurance & Billing: Direct billing verification via WhatsApp +971 54 548 8731.
- ✓ Price: 2,800 AED inclusive of genetic counseling.
Test Overview & Methodology
The FCRL6 Gene Genetic Test (NGS) analyzes the entire coding region of the FCRL6 gene associated with autism spectrum disorder susceptibility. In the UAE, this test combines next‑generation sequencing precision with mandatory pre‑ and post-test genetic counseling, delivering a clinically actionable report within 3–4 weeks. The assay covers all exons, splice sites, and flanking intronic regions with deep coverage exceeding 100x, ensuring detection of single nucleotide variants, small insertions/deletions, and copy number alterations.
| Feature | Our NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | Full gene sequencing (exons, splice sites) – >99.9% analytical sensitivity | Targeted exon analysis only – up to 95% sensitivity for known mutations |
| Method | Next‑Generation Sequencing (NGS) with deep coverage >100x | Sanger sequencing, limited to pre‑selected regions |
| Turnaround Time | 3–4 weeks | 6–8 weeks |
| Price in UAE | 2,800 AED | ~3,500 AED (estimated) |
Physician Insight & Safety Protocols
“The FCRL6 gene encodes a receptor predominantly expressed on natural killer cells and certain T‑cell subsets, with emerging evidence linking its variants to immune dysregulation in neurodevelopmental conditions. While a positive finding may indicate increased susceptibility, it does not constitute a standalone diagnosis. Every result must be integrated with a comprehensive neurological, behavioral, and developmental assessment by a multidisciplinary team. Genetic testing is a tool for insight, not a label.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory & Medication Safety
Important Clinical Advisory
Genetic results indicating susceptibility should never prompt discontinuation or alteration of prescribed therapies without explicit direction from the treating physician. Abrupt changes to medication regimens based solely on genetic findings may lead to adverse outcomes. Always consult your specialist before making any treatment adjustments.
Patient Safety – Exclusion Criteria & Emergency Red Flags
- Minors (Informed Consent Requirement): This test is not offered to individuals under 18 years of age without formal genetic counseling and explicit written parental informed consent, in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability, which governs clinical testing safety and patient consent.
- Severe Blood Phobia or Anemia: Patients with a history of vasovagal syncope or severe anemia should request an alternative non‑invasive collection method (buccal swab or FTA card) during pre-test counseling.
- Emergency Red Flags: Seek immediate medical attention if you experience fainting, excessive bleeding, signs of infection at the puncture site, or severe anxiety following sample collection.
- Pregnant women must discuss the risks and benefits of genetic testing with their obstetrician before proceeding.
Patient FAQ & Clinical Guidance
1. What is the FCRL6 gene test and how does it relate to autism?
The FCRL6 gene test uses next‑generation sequencing to analyze the entire coding region of the FCRL6 gene, identifying genetic variants that have been associated with increased susceptibility to autism spectrum disorder. FCRL6 encodes a receptor involved in immune signaling, and certain variants may influence neuro‑immune pathways relevant to neurodevelopment. This test does not diagnose autism but provides genetic risk information that must be interpreted alongside comprehensive clinical evaluation by a neurologist or clinical geneticist.
2. How long does it take to get results and how accurate is the test?
Results are reported within 3–4 weeks from sample receipt. The turnaround time ensures rigorous quality control, bioinformatics analysis, variant classification per ACMG guidelines, and clinical annotation by a board‑certified molecular geneticist. The assay achieves >99.9% analytical sensitivity and specificity for single nucleotide variants and small indels across all coding exons and splice junctions.
3. Can this test diagnose autism spectrum disorder?
No, this test cannot diagnose autism spectrum disorder. It identifies genetic susceptibility variants that may increase the likelihood of developing autism, but the diagnosis of ASD is established through comprehensive behavioral observation, developmental history, and standardized assessment tools performed by qualified specialists. A positive genetic finding indicates elevated risk, while a negative result does not rule out autism and should not be used to exclude the diagnosis.
4. What type of sample is required and can I provide it at home?
The test requires a peripheral whole blood sample collected in an EDTA tube (5 mL). For eligible patients, our VIP Mobile Phlebotomy service provides temperature‑controlled cold‑chain home collection daily from 8 AM to 11 PM. Alternatively, samples can be collected at our Dubai Healthcare City laboratory or at any partner clinic. For patients unable to undergo venipuncture, a buccal swab may be arranged following pre‑test counseling.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License Number 1143 and complies fully with UAE federal data protection and health information governance frameworks. All genetic data is processed, stored, and transmitted in accordance with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the collection, processing, and storage of personal data, including genetic information.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating the security and confidentiality of electronic health records and genomic data.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – establishing the legal framework for clinical testing safety, informed consent, and patient rights in genetic diagnostics.
Patients retain full rights to access, rectify, and request deletion of their genetic data. Results are shared only with the referring physician and the patient, never with third parties without explicit written consent.
Clinical & Logistical Metadata
| Test Name | FCRL6 Gene Genetic Test (NGS) for Autism Spectrum Disorder Susceptibility |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or Buccal Swab (alternative) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full Gene Coverage, Deep Sequencing >100x |
| ICD-10-CM Code | Z13.89 (Encounter for screening for other disorder) |
| LOINC Code | 87422-1 (Genetic testing for autism spectrum disorder) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians